eversyn
This company offers proprietary technology that is based on the efficient use of novel, gmo-free biocatalytic cascades.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.7m | Seed | |
| Total Funding | 000k | ||
Related Content
Eversyn is an innovative biotech startup that specializes in the production of nucleotide sugars and human milk oligosaccharides (HMOs) through advanced biocatalyst engineering. The company operates in the biotechnology and pharmaceutical markets, serving clients such as pharmaceutical companies, research institutions, and manufacturers of specialty carbohydrates.
Eversyn's core technology revolves around cell-free biosynthesis, which involves designing and engineering multi-enzyme pathways to produce bioproducts. This method allows the company to produce nucleotide sugars at a significantly lower cost compared to traditional methods. These nucleotide sugars are essential for various applications, including the synthesis of HMOs and the glycosylation (attachment of sugars) of therapeutic proteins, which are crucial for developing effective and safe medications.
The company was founded as a spin-off from the Max Planck Institute Magdeburg and is supported by a team of experienced scientists and business professionals. Eversyn's innovative approach has led to numerous patents and high-profile collaborations, underscoring its credibility and expertise in the field.
Eversyn's business model is based on the production and sale of nucleotide sugars and HMOs. By leveraging its proprietary synthesis methods, the company can offer these products at a more affordable price, making them accessible for large-scale applications. Revenue is generated through direct sales to pharmaceutical companies and research institutions, as well as through partnerships and collaborations with other biotech firms.
In summary, Eversyn is a cutting-edge biotech company that has developed a cost-effective method for producing nucleotide sugars and HMOs, serving the pharmaceutical and biotechnology markets with innovative and affordable solutions.
Keywords: biotechnology, nucleotide sugars, human milk oligosaccharides, biocatalysts, cell-free biosynthesis, pharmaceutical, glycosylation, Max Planck Institute, cost-effective, enzyme pathways.